3-(4-Phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine, also known as ibrutinib N-2, is a light brown solid. It can be prepared from 3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine and 4-phenoxybenzeneboronicacid by Suzuki coupling reaction[1]. Ibrutinib N-2 is often used in the preparation of the marketed drug PCI-32765 (IMBRUVICAVR)[2]. PCI-32765 is aIbrutinib -BTK inhibitor and can be used as an anticancer drug to treat B cell cancers like mantle cell lymphoma and chronic lymphocytic leukemia.

Verwenden

As Ibrutinib intermediates, 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine can be used as organic synthesis intermediates and pharmaceutical intermediates, mainly used in laboratory research and development and chemical production processes.

Application

3-(4-Phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine is an intermediate for the synthesis of ibrutinib, which is mainly used in drug synthesis and related experimental studies.

Synthese

2 g of 3-iodo-4-aminopyrazolo[3,4-d]pyrimidine (7.7 mmol),3.28 g p-phenoxybenzeneboronic acid (15.4 mmol)And 5.28 g of K3PO4 (23.0 mmol) were dissolved in 25 mL of dioxane and 10 mL of water.After stirring for 5-8 minutes, argon gas was passed for 20 minutes.An additional 1.4 g of tetrakis(triphenylphosphine)palladium (1.2 mmol) was added.After heating again for 10 minutes, the heating was started, and the reaction was carried out at 120 C for 24 hours.After the reaction was completed, it was cooled to room temperature, stirred for 24 hours to wait for product to precipitate, and the reaction mixture was washed with 25 mL of water and filtered.The filtered solid was again washed with 75 ml of methanol, washed with 50 mL of ethanol, and dried in a dry box.There was obtained 1.75 g of 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine in a yield of 75%.

Einzelnachweise

[1] Rampalli, S, et al. Process for the Preparation of Ibrutinib. PCT Int. Appl. 2017; 134588.
[2] Dasar G, et al. One-step synthesis of magnetically recyclable palladium loaded magnesium ferrite nanoparticles: application in synthesis of anticancer drug PCI-32765. Inorganic and Nano-Metal Chemistry, 2020; 50.

3-(4-Phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

3-(4-Phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
SyncoZymes (Shanghai) Co., Ltd.,	+86-13681683526（Wechat）	lchen@syncozymes.com	China	286	58
Changzhou uniringchem Co., Ltd.	13585446801	sales@uniringchem.com	China	69	58
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	20120	58
Shaanxi Xianhe Biotech Co., Ltd	+86-17709210191; +86-17709210191	Jerry@xhobio.com	China	906	58
Hebei Zhuanglai Chemical Trading Co Ltd	+86-16264648883	niki@zlchemi.com	China	7245	58
Capot Chemical Co.,Ltd.	+86-（0）57185586718 +86-13336195806	sales@capot.com	China	29640	60
Shanghai Daken Advanced Materials Co.,Ltd	+86-2158073036	info@dakenam.com	China	14033	58
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1803	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21585	55
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60

330786-24-8()Verwandte Suche:

---

• 2) 3-(4-PHENOXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
• ibrutinib N-2
• 1H-Pyrazolo[3,4-d]pyriMidin-4-aMine, 3-(4-phenoxyphenyl)-
• Ibrutinib intermeidate N-2
• Ibrutinib INT1
• Ibrutinib Impurity 8
• -(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine
• PCI-32765 (IBRUTINIB) INTERMEDIATE(N-2)
• 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylamine (N-2)
• 5-(3-Phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine
• 5-(4-Phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine
• 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-y
• 3-d]pyriMidin-4-ylaMine
• 5-(4-phenoxyphenyl)-7H-pyrrolo[2
• 3-(4-phenoxyphenyl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine
• Ibrutinib impurity 3/ 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
• 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine/Ibrutinib impurity
• 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidine
• Ibrutinib intermediates N-2
• 3-(4-phenoxyphenyl)-1 H- pyrazolium [3,4- D] pyrimidine-4-amine
• Ibrutinib deacryloylpiperidine
• Ibrutinib N-Despiperidinyl Impurity
• 5- (4-phenoxyphenyl) -7H-pyrrolio [2,3-d] pyrimidin-4-ylamine
• Ibrutinib intermediate 2
• 5-(4-PHENOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINE/3-(4-PHENOXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
• 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine ISO 9001：2015 REACH
• IbrutinibintermeidChemicalbookateN-2
• 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine
• Ibrutinib Impurity 46
• 10-Morpholineethanamine,N-(cyclohexylcarbonimidoyl)-
• 3-(4- phenoxyphenyl) -1H- pyrazolo [3,4-d] pyrimidine -4- amine
• Ibrutinib deacryloylpiperidine (Ibrutinib Impurity)
• Ilutinib impurity 8
• 3-(4-Phenoxy Phenyl)-1H-pyrazole [3,4-d]pyrimidin-4-Amine
• 3-(4-Phenoxyphenyl)-1H-pyrazoleand[3,4-d]pyrimidine-4-amine
• 3-(4-Phenoxypheny)- 1Hpyrazolo[3.4-dlpyrimidin-4-amine
• 3-(4-Phenoxyphenyl)pyrazolo[3,4-D]pyrimidin-4-amine
• 4-Amino-3- (4-phenoxyphenyl) -1H pyrazole [3,4-D] pyrimidine
• Ibrutinib intermediate
• 3- (4-phenoxyphenyl) -1H-4-amino - [3,4-D] pyrazolopyrimidine
• Ibrutinib deacryloylpiperidine, 10 mM in DMSO
• Ibrutinib impurity ZZ17 reference substance
• 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (Intermediate of Ibrutinib)
• 5-（4-phenoxyphenyl）-7H-pyrrolo［2，3-d］pyriMidin-4-ylaMin
• 4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidine
• 3-(4-PHENOXYPHENYL)-1H-PYRAZOLO[4-D]PYRIMIDIN-4-AMINE
• 330786-24-8
• 30786-24-8
• 330786-24-3
• 370786-24-8
• 330789-24-8
• Ibrutinib
• Anticancer
• 330786-24-8